Compare Okta, Inc. (OKTA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Viatris Inc — how do they compare? Okta, Inc. trades at $232.2 (market cap $38.50B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Okta, Inc. is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and Viatris Inc for 57 Days on average.
| OKTA | VTRS | |
|---|---|---|
Market Cap | $38.50B | $20.03B |
Volume | 2,479,621 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $220.21 | $18.27 |
52-Week Low | $62.93 | $9.74 |
Typical Hold Time | 44 Days | 57 Days |
Enterprise Value | $36.25B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA's stock trades at $232.13, up 6.48% in the last 24 hours, reflecting strong momentum. The technical outlook is bullish, with the price near resistance at $232. Recent earnings beats and a strategic focus on AI agent security, highlighted at the Oktane 2026 conference, support positive sentiment. However, valuation ratios like a P/E of 132.66 and P/S of 12.74 indicate a premium, while the company has only recently achieved profitability with a net income margin of 1.07% in 2025.
The outlook is cautiously optimistic, driven by revenue growth and AI positioning, but high valuation and competitive pressures pose risks. Analyst consensus is strongly bullish with a 73.58% buy rating, though the current price exceeds the consensus target of $201.30, suggesting near-term consolidation may occur. Investors should weigh growth potential against premium multiples and market volatility.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
